PRCT Stock Summary and Trading Ideas (Procept Biorobotics | NASDAQ:PRCT)

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

Procept Biorobotics trades on the NASDAQ stock market under the symbol PRCT.

As of September 14, 2026, PRCT stock price climbed to $21.02 with 1,531,380 million shares trading.

PRCT has a beta of 0.64, meaning it tends to be less sensitive to market movements. PRCT has a correlation of 0.02 to the broad based SPY ETF.

PRCT has a market cap of $1.20 billion. This is considered a Small Cap stock.

Last quarter Procept Biorobotics reported $94 million in Revenue and -$.47 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.01.

In the last 3 years, PRCT traded as high as $103.81 and as low as $16.67.

The top ETF exchange traded funds that PRCT belongs to (by Net Assets): VTI, IWM, VB, VBK, VXF.

PRCT has underperformed the market in the last year with a return of -45.6%, while the SPY ETF gained +16.8%. In the last 3 month period, PRCT fell short of the market, returning -24.1%, while SPY returned +3.4%. However, in the most recent 2 weeks PRCT has outperformed the stock market by returning +0.9%, while SPY returned -1.1%.

PRCT support price is $19.67 and resistance is $21.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRCT shares will trade within this expected range on the day.